CRP and spondyloarthropathy: This study used the Assessment of SpondyloArthritis International Society response rate 20/40/70 (ASAS 20/40/70), Bath Ankylosing Spondylitis Disease Activity Index 20/50/70 (BASDAI 20/50/70), Ankylosing Spondylitis Disease Activity Score on the basis of C-reactive protein level (ASDAS-CRP), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), and other indices to measure the efficacy of Kunxian capsules in the treatment of AS patients.